Home › Funds › Versant Venture Management, LLC › CRSP
Versant Venture Management, LLC position in CRSP
CRISPR THERAPEUTICS AG · Health Care
Versant Venture Management, LLC reported holding 148,831 shares of CRSP (CRISPR THERAPEUTICS AG) in its Q3 2026 13F filing — a position valued at US$8.2M, representing 7.55% of its reported portfolio and ranking #6 among its reported holdings. Versant Venture Management, LLC has disclosed CRSP holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Versant Venture Management, LLC's CRSP position evolved
Versant Venture Management, LLC first disclosed a stake in CRSP in Q3 2023 at 498,558 shares (US$22.6M). The position peaked in Q1 2024 at 498,558 shares, worth US$34.0M. Across 13 filings, Versant Venture Management, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 11 time(s). The most recent filing (Q3 2026) shows 148,831 shares valued at US$8.2M. Notable position changes include a 70% trim in Q3 2025 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 498.56K | $22.63M | New |
| Q4 2023 | 498.56K | $31.21M | Hold |
| Q1 2024 | 498.56K | $33.98M | Hold |
| Q2 2024 | 498.56K | $26.93M | Hold |
| Q3 2024 | 498.56K | $23.42M | Hold |
| Q4 2024 | 498.56K | $19.62M | Hold |
| Q1 2025 | 498.56K | $16.97M | Hold |
| Q2 2025 | 498.56K | $24.25M | Hold |
| Q3 2025 | 148.83K | $9.65M | Reduce |
| Q4 2025 | 148.83K | $7.80M | Hold |
| Q1 2026 | 148.83K | $7.08M | Hold |
| Q2 2026 | 148.83K | $8.12M | Hold |
| Q3 2026 | 148.83K | $8.23M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRSP and 13F data
CRSP (CRISPR THERAPEUTICS AG) is a Health Care company. 30 other funds we track also report a position in CRSP — the largest reported positions include ARK Invest (US$556.3M), Orbis Allan Gray Ltd (US$297.2M), GSK plc (US$144.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRSP
- ARK Invest 10.06M sh · $556.34M · Q3 2026
- Orbis Allan Gray Ltd 5.45M sh · $297.20M · Q2 2026
- GSK plc 2.61M sh · $144.30M · Q3 2026
- SR ONE CAPITAL MANAGEMENT, LP 2.04M sh · $111.19M · Q2 2026
- Amova Asset Management Americas, Inc. 1.45M sh · $80.36M · Q3 2026
- EcoR1 Capital, LLC 1.39M sh · $75.77M · Q2 2026
- NEA Management Company, LLC 1.06M sh · $57.73M · Q2 2026
More on Versant Venture Management, LLC
FAQ
How long has Versant Venture Management, LLC held CRSP?
Versant Venture Management, LLC has disclosed CRSP holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Versant Venture Management, LLC's current position in CRSP?
As of Q3 2026, Versant Venture Management, LLC holds 148.83K shares of CRSP (CRISPR THERAPEUTICS AG), valued at $8.23M, representing 7.55% of its reported portfolio and ranking #6.
Has Versant Venture Management, LLC been buying or selling CRSP?
In the latest 13F filing (Q3 2026), Versant Venture Management, LLC held unchanged its position in CRSP. The position peaked in Q1 2024 at 498.56K shares.
Which other funds hold CRSP?
Other major institutional holders of CRSP include ARK Invest, Orbis Allan Gray Ltd, GSK plc, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.